Phase 2 B-cell Acute Lymphoblastic Leukemia Clinical Trials

25 recruitingPhase 2

What is a Phase 2 trial?

Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.

Showing 120 of 25 trials

Recruiting
Phase 1Phase 2

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca163 enrolled80 locationsNCT06137118
Recruiting
Phase 1Phase 2

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic LeukemiaMinimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Amgen104 enrolled4 locationsNCT07134088
Recruiting
Phase 1Phase 2

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

B-cell Non Hodgkin LymphomaB-cell Acute Lymphoblastic Leukemia
University of Colorado, Denver45 enrolled1 locationNCT04544592
Recruiting
Phase 1Phase 2

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

B-cell Acute Lymphoblastic Leukemia
Merck Sharp & Dohme LLC90 enrolled67 locationsNCT06395103
Recruiting
Phase 1Phase 2

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

T-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL+3 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 1Phase 2

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca83 enrolled26 locationsNCT07109219
Recruiting
Phase 2Phase 3

NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)

Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Relapsed/Refractory Non-Hodgkin Lymphoma+2 more
Health Institutes of Turkey40 enrolled4 locationsNCT07502118
Recruiting
Phase 1Phase 2

Co-administration of CART22-65s and huCART19 for B-ALL

B-cell Acute Lymphoblastic LeukemiaB Lineage Lymphoblastic Lymphoma
Stephan Grupp MD PhD93 enrolled1 locationNCT05674175
Recruiting
Phase 1Phase 2

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaChronic Lymphocytic Leukemia+8 more
Vironexis Biotherapeutics Inc.32 enrolled9 locationsNCT06533579
Recruiting
Phase 2

A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center60 enrolled1 locationNCT07153796
Recruiting
Phase 1Phase 2

Study of YK012 in B-cell Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia
Excyte Biopharma Ltd46 enrolled12 locationsNCT06580301
Recruiting
Phase 1Phase 2

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

B-cell Acute Lymphoblastic Leukemia
Cellectis S.A.52 enrolled19 locationsNCT04150497
Recruiting
Phase 1Phase 2

A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

B-cell Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.47 enrolled9 locationsNCT05667506
Recruiting
Phase 2

CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL

B-cell Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University37 enrolled1 locationNCT05470777
Recruiting
Phase 2

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

B-cell Acute Lymphoblastic Leukemia
Pediatric Transplantation & Cellular Therapy Consortium95 enrolled24 locationsNCT03509961
Recruiting
Phase 2

CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

Relapsed B-cell Acute Lymphoblastic LeukemiaRefractory B-cell Acute Lymphoblastic Leukemia
Beijing Yongtai Ruike Biotechnology Company Ltd100 enrolled1 locationNCT06179524
Recruiting
Phase 2

Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL

Precursor B-Cell Acute Lymphoblastic Leukemia
First Affiliated Hospital of Zhejiang University36 enrolled1 locationNCT06754267
Recruiting
Phase 2

Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL

Precursor B-Cell Acute Lymphoblastic Leukemia
First Affiliated Hospital of Zhejiang University20 enrolled1 locationNCT06742515
Recruiting
Phase 2

Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL

B-cell Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University30 enrolled1 locationNCT06393985
Recruiting
Phase 2

Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.

B-cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT06608732